FL-WELLVII
3.1.2023 14:01:43 CET | Business Wire | Press release
Wellvii, manufacturer of connected smart devices for health and wellbeing, today announced a partnership with Care Daily, a software technology company with AI-based Caregiver services for senior care, to bring integrated solutions for aging-in-place experiences.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230103005097/en/
myWellvii Platform (Photo: Business Wire)
Patients are now, more than ever, extremely receptive to personal health management solutions. The consumerization and democratization of healthcare gained significant momentum prior to the pandemic and COVID-19 has further accelerated this trend. The partnership between Wellvii and Care Daily will let users take control of their wellbeing with self-monitoring and give them an enhanced view into their overall health.
“The core devices of the myWellvii Platform; the Wellvii MVS1, Wellvii Go wearable, and Wellvii Weight scale in conjunction with the Care Daily’s AI and IoT platform will enable a comprehensive solution for families to measure their health and wellness and improve their well-being.” Mark Khachaturian, PhD CEO of Wellvii.
“Care Daily has commercialized the most advanced AI Caregiver intelligence which, until today, has primarily captured data from ambient sensors in homes to learn lifestyle patterns, trends, and activities of daily living,” said David Moss, CEO of Care Daily. “Integrating Wellvii’s core devices with our AI Caregiver services unifies the lifestyle trends in the home with the biometric trends from the resident’s body, providing an unparalleled understanding of how this person is truly doing. Senior care solutions providers are excited about the opportunity to bring these differentiated services to market under their own brands.”
Both companies are in discussions with major providers to trial the combined technology in homes. Top use cases include senior care and chronic care management.
About Wellvii
Wellvii enables the delivery of healthcare at any address through its all in one comprehensive, clinically validated, connected device that measures 11 vital parameters from the finger, including an oscillometric blood pressure finger cuff. Wellvii also introduces a comprehensive wellness scoring system including the first at-home “stress test” using its proprietary fitness challenge. For more information about the myWellvii platform, click here.
1The Wellvii MVS is not a medical device and cannot be used for clinical applications in the USA. The Wellvii VitalDetect has CE Mark clearance as a Class IIa medical device in Europe. For more information on the Wellvii VitalDetect for Europe, click here. Wellvii has 60 patents issued (57 US, 2 UK, 1 EU).
Follow Wellvii on Twitter, LinkedIn, Instagram, and Facebook.
To directly contact Wellvii: info@wellvii.com.
About Care Daily
Care Daily is the only white-label home health AI and IoT SaaS that deeply personalizes the delivery of senior care through large brands. Care Daily is backed by the NIA, and the company’s award-winning AI Caregiver software intelligence is the first to achieve scientific validation for senior care assistive services in homes. Care Daily’s AI Caregiver personality and services are uniquely configurable by partners for maximum differentiation against other brands and solutions providers. The intelligence detects falls in real-time, uncovers hidden health problems, and brings families and professional caregivers together to care for seniors. Care Daily’s white-labeled solutions are utilized by some of the largest brands to quickly deploy and continually enhance personalized healthcare services for seniors in homes and communities. To learn more, visit www.CareDaily.ai or connect with us on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230103005097/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom